AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...

The randomized, double-blind WAYPOINT trial tested Tezspire’s efficacy and safety in adults with severe CRSwNP who continued ...

known as nasal polyps. People with CRSwNP experience symptoms such as nasal obstruction, loss of smell, facial pressure, sleep disturbance, infections, and nasal discharge. Data from ANCHOR-1 and ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

While fractional exhaled nitric oxide can be useful, “studies show that it is more useful for to monitor the symptoms rather ... sinusitis, nasal polyps, clubbing, and isolation of suspicious ...

The panic of an extreme allergic reaction, or anaphylaxis, is the reality for millions of kids and adults across the ... for people experiencing nasal polyps and congestion, since it's delivered ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological <a target=_blank ...

(PRESS RELEASE) LONDON, 14-Oct-2024 — /EuropaWire/ — GSK plc (LSE/NYSE: GSK) has revealed encouraging results from the Phase III ANCHOR clinical trials assessing the efficacy and safety of depemokimab ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...